chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a nurse refers to a patient of unknown age. Patient medical history and current condition was not reported. On an unknown date the patient was vaccinated with PNEUMOVAX 23, of dose 0.5 ml. It was reported that the patient missed a dose of PNEUMOVAX 23 due to a product quality complaint. Also reported that product quality complaint was filed. No adverse effect was reported. The outcome of the event was unknown. Additional information has been requested.
Chills, muscle aches, joint pain starting about an hour and a half after getting the vaccine, and lasting for 3 days.
Chills, body aches, head congestion, headache, low grade fever (100.5) at its highest. Started at about 7 am on 3/20 and lasted to 7 :30 a.m. the next day. Still feel a little tired and weak with very mild headache.
Within a couple weeks I developed shingles on my abnomen and I still have subsequent nerve pain. Most importantly and most concerning is the consistent chest pain since having the vaccine. It has been persistent to the point where I recieved EMS transport from work because the of the chest pain. I still have them to this day. It is incresingly worse if I'm involved with strenuous activities such as fire deparment and ems related tasks, as well as working out trying to stay fit and healthy. This pain is sharp and i can feel it all throughout the day. With research linking multiple deaths and other health concerns I am sincerly afriad that I'm going to suffer a cardiac event or that I'm developing blood clots.
left ankle is only a little stiff; unexpected therapeutic benefit; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (unexpected therapeutic benefit) and JOINT STIFFNESS (left ankle is only a little stiff) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028A21A) for COVID-19 vaccination.     The patient's past medical history included Psoriatic arthritis. Concurrent medical conditions included Penicillin allergy (penicillin and all derivatives) and Drug allergy (Bactrim, Zovirax).   On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 30-Apr-2021, the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (unexpected therapeutic benefit). On an unknown date, the patient experienced JOINT STIFFNESS (left ankle is only a little stiff). At the time of the report, THERAPEUTIC RESPONSE UNEXPECTED (unexpected therapeutic benefit) and JOINT STIFFNESS (left ankle is only a little stiff) outcome was unknown. Not Provided.          Patient stated that it was after the second dose that symptoms seemed to have gotten better. Prior to, patient reports feeling like going crazy with the psoriatic burns, itching, and pain. Patient states that knees would swell up and it would hurt in eyes. Patient reports the symptoms were intolerable and could not help. Patient wants to report that skin was clearing up and left ankle which used to hurt to bend now was only a little stiff.
The morning of 02/09/2023, I woke up with a cough, fever, loss of appetite, and fatigue. I tested myself for COVID-19 and was positive. My symptoms continued through to 02/11/2023. I went to a local urgent care who tested me again and confirmed COVID-19 and prescribed Paxlovid. My symptoms improved after taking that. By Sunday, I was still fatigued with loss of appetite. I still had some congestion but that was better. On 02/14/2023, I was still testing positive. On 02/16/2023, I was testing negative. I never had any trouble breathing really, it was all just sinuses and sore throat. From the 16th onward, I gradually got my appetite and energy back. Within a week or 10 days it was all past.
Soreness and itching at injection site--started 8 hrs post-vaccine and continued for 36 hours. Fever (100.3° - 101.3°), overall aching and muscle stiffness, headache-- started approximately 18 hours post-vaccine and lasted 24 hrs.
Pt recvd vax & the day p/exp nausea & vomiting which lasted 24 hrs;
Information has been received from a registered nurse concerning a 52 year old female with LISINOPRIL (WAES#: 0903USA02280) and PENICILLIN allergy and dialysis who on 24-JAN-2009 was vaccinated IM with a 40mcg dose of HEP B vaccine into the left deltoid. 1 week later, the patient developed a sore arm. The patient went to her physician to have it examined and the physician stated the patient had a "nerve spasm" possibly related to the HEP B vaccine that she was given. The nurse stated "the physician informed the patient that the HEP B vaccine may have crystallized in the vial and then it was given to the patient." The nurse stated she did not see any crystallization in the vaccine vial when it was administered. Nurse also reported that this was not the first time this patient was given HEP B vaccine and she has never had a reaction in the past. As of 11-MAR-2009 the patient's nerve spasm was not recovered. Additional information has been requested.
Fatigue, generalized aches and bone pain, malaise, cough, severe sore throat.
Upper Arm still hurts and no relief. Constantly fatigued.and runny nose.
91 yr old male presented in ER 01/05/2022  via EMS from daughter's home whom he lives with. She found him on the bathroom floor.  He does have dementia that is progressively worsening per family. Patient was in the ER yesterday,  01/04/2022, after having a fall.  Daughter reported patient developed a cough two nights prior and has been weak and not himself.  Tested + for COVID 01/04/2022. Patient is a DNR/DNI. Hospitalized 01/05/2022. At some point was transferred to Hospice and passed away 01/09/2022.
Inappropriate schedule of vaccine administered; Experienced bilateral, persistent tinnitus soon after receiving first dose, and worsens with each subsequent dose; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 60-year-old male patient received bnt162b2 (BNT162B2), on 25Mar2021 as dose 2, single (Lot number: EP6955) at the age of 60 years for covid-19 immunisation. The patient's relevant medical history included: "CTCL" (unspecified if ongoing); "known allergies: PCN" (unspecified if ongoing); "known allergies: bee venom" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: bnt162b2 (DOSE 1, Batch/Lot No: EN6198), administration date: 04Mar2021, when the patient was 60-year-old, for COVID-19 immunization, reaction(s): "Experienced bilateral, persistent tinnitus soon after receiving first dose". The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 25Mar2021, outcome "unknown", described as "Inappropriate schedule of vaccine administered"; TINNITUS (non-serious) with onset 2021, outcome "not recovered", described as "Experienced bilateral, persistent tinnitus soon after receiving first dose, and worsens with each subsequent dose". The events "experienced bilateral, persistent tinnitus soon after receiving first dose, and worsens with each subsequent dose" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Experienced bilateral, persistent tinnitus soon after receiving first dose, and worsens with each subsequent dose. Evaluated by ENT and audiologist. MRI ordered, no causes identified.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300321222 same patient/AE, different drug dose;
The pt experienced swelling of the left thigh with redness around the site at the injection 10 cm in diameter and tenderness. No fever.
Mother reports patient had a little fever Sat. 10/19 in the AM, gave her Motrin, sent to babysitter above she developed temp 105 degrees, was lethargic. Mother took her ER where she was given Tylenol and Motrin, temp down, told patient had probable viral infection. No further high temps that day, well now.
Discharge Provider:  Primary Care Provider:  Admission Date: 3/16/2023 Discharge Date: Mar 23, 2023  PRESENTING PROBLEM: Acute respiratory insufficiency [R06.89] Infection due to human metapneumovirus (hMPV) [B34.8] COVID-19 [U07.1] Acute respiratory failure due to COVID-19 (HCC) [U07.1, J96.00]   HOSPITAL COURSE:  a 66 y.o. male with a past medical history of Parkinson's disease with psychosis, OSA, reported history of stroke, history of kidney stones, history of DVT typically on Xarelto, hypothyroidism,  and multiple recent falls with recent large right gluteal hematoma 03/02/2023 requiring hospitalization. Patient presented from subacute rehab. with fevers and a fall out of bed.  Patient was reportedly saturating mid 80s on room air at the facility. Upon arrival to the emergency department he was noted to be hypoxemic initially requiring non-rebreather but able to wean down to 4 L nasal cannula.  He was noted to be positive for COVID-19 and metapneumovirus. He was admitted to the internal medicine service. He was started on Remedesivir and dexamethasone. Also received intermittent doses of IV lasix and supportive care. His oxygen was able to be weaned to room air. PT/OT recommended SNF. Patient was discharged on 3/23/2023  5:23 PM
headache; low grade fever; chills; body ache; trouble sleeping; night sweats; The initial case was missing the following minimum criteria: Duplicate cases Upon receipt of follow-up information on 24Feb2021, this case now contains all required information to be considered valid This is a spontaneous report from a contactable consumer (patient). A 55-year-old male patient received bnt162b2 (BNT162B2, formulation: solution for injection, Batch/Lot number: el3247, expiry date not provided) via an unknown route of administration, administered in Arm Right on 18Feb2021 11:45 AM as DOSE 2, SINGLE (at the age of 55-year-old) for covid-19 immunisation. The patient's medical history was not provided. Historical vaccine included first dose of bnt162b2(BNT162B2) administered in Arm Right on 28Jan2021 11:45 AM as DOSE 1, SINGLE (at the age of 55-year-old) for covid-19 immunisation. Patient had not received any other vaccine within 4 weeks. Patient had not been diagnosed with COVID-19 prior to vaccination and had not been tested since the vaccination. The patient had no known allergies. The patient did not receive any concomitant medications within 2 weeks of vaccination with the Covid-19 vaccine. On 19Feb2021, after received the second dose of the Pfizer vaccine, patient experienced headache, low grade fever, chills, body ache, trouble sleeping and night sweats. The patient underwent lab tests which included body temperature: low grade fever on 19Feb2021 and nasal swab for sars-cov-2 antibody test: negative on 02Feb2021. The patient was not received any treatment for events. The outcome of the events was unknown.  No follow-up attempts are needed. No further information is expected.
Itchy rash developed at injection site yesterday. It was small - similar to a mosquito bite. When I woke up this morning it had expanded to  about 1-2 inches and is hard, a little painful but not itchy just yet.
Experienced diarrhea / has resolved; Is experiencing intermittent soft stools; This case was reported by a consumer via call center representative and described the occurrence of diarrhea in a 72-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on 28th July 2020).   On 16th November 2020, the patient received the 2nd dose of Shingrix. In November 2020, less than a week after receiving Shingrix, the patient experienced soft stools. On 21st November 2020, the patient experienced diarrhea. On an unknown date, the outcome of the diarrhea was recovered/resolved and the outcome of the soft stools was recovering/resolving.   It was unknown if the reporter considered the diarrhea and soft stools to be related to Shingrix.  Additional details were provided as follows: There was no events associated with dose 1 of vaccine. Patient received the 2nd dose of Shingrix and 5 to 6 days after the vaccination patient experienced diarrhea and intermittent soft stools. The formaulation for doses were not provided. It was reported that the diarrhea has resolved. The patient did not wish to provide specific demographics. The reporter did not consent to follow up
Patient is fully vaccinate and booted on 11/17/2021.  COVID + on 12/6/2021.  Hospitalized for 3 days starting 12/6/2021.  Patient presented to hospital S/P MVC, found to be COVID positive. All imaging workup was negative, including neurological. Cleared by trauma. Covid is asymptomatic.  He did have Hypoxemia requiring supplemental oxygen. Right pulmonary contusion. Right pulmonary contusion. Pneumonia due to COVID-19 virus.  IV decadron, Breo inhaler.      Stable
On the evening of the immun date pt reportedly had sz activity witnessed only by the parents @ home; went to ER; t39.2; PE otherwise normal x/OM
Initial and follow-up information has been received from a nurse practitioner concerning an approximately 27 year old female veterinarian technician, who on 07-MAY-2007 was vaccinated intramuscularly  with a 0.5 ml first dose of GARDASIL (Lot# 657617/0384U). On 07-MAY-2007 (previously reported as during the next 24 hours), the patient experienced fever, nausea, diarrhea, low back pain, vomiting, her spine ached, and it hurt for her to move. Unspecified medical attention was sought. The patient then recovered within 24 hours from the fever, nausea, diarrhea, low back pain, and vomiting on an unspecified date. Additional information has been requested.  Additional information is not expected.
Hep B given around (10:15-10:30 AM) 1/7/03. Came home from school; right leg shaking. Afebrile in PM. Mother called 3:09 PM.
pt recvd vax & devel sz generalized tonic-clonic w/ fever 102.9; occured x 2 w/in 1st 24 hrs;
No adverse effects; accidenlally given a third dose or VAQTA; This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions/allergies and concomitant medications were not reported. On 12-NOV-2019 the patient was accidentally vaccinated with third dose of hepatitis a vaccine, inactivated (VAQTA) vial (25/0.5 unit not specified) via intramuscular route for prophylaxis (dose, lot # and expiry date were not reported) (extra dose administered). It was confirmed that, the dose was not given due to product confusion. The patient did not experience any adverse effects. Product quality complaint was not involved.
she has had a cramp in her left foot; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A female patient received bnt162b2 (BNT162B2), administration date Jan2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MUSCLE SPASMS (non-serious) with onset Jan2021, outcome "unknown", described as "she has had a cramp in her left foot".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient was given Varivax when she had MMR within the past 4 weeks. It was not reported to the pharmacy that she received MMR prior.
fever of up to 101.5; extreme body ache; chills; headache, fatigue - barely able to roll over much less get out of bed.   Felt like bad flu.   Took tylenol.    Woke up next day symptom free.
Pt had headache, arthralgia, anorexia, nausea, pharyngitis, malaise, lasting approximately 24 hours.
The pt experienced hives, itching on legs, buttocks, back had some response to Benadryl. The next day had hives on waist and belly, 2 days later had hives on chest, scalp. The pt had 2 trips to urgent care, treated with Benadryl, methylprednisolone, Atarax with full recovery by 4 days post vax.
Fever of 100.5 x 2 days Myalgias, unable to get out of bed x 2 days
58 day old baby given 2 month routine vaccines in office in the morning.  Mild nasal congestion on exam.  That evening, apnea and possible seizure. In ER, respiratory failure, cardiac arrest. Resuscitation successful. Transferred to higher level of care
Patient states she developed hives and rash on her body that resolved with diphenhydramine. Patient states that this lasted for one day and started 24 hours after vaccine.
Within 3 days of persistent crying and fussiness. LOF onset with immunizations within 4-5 hrs. No treatment.
Information has been received from physician concerning a 12-month-old male who was recently vaccinated with a dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live.  Concomitant vaccinations included a dose of varicella virus vaccine live and a dose of pneumococcal 4 6B 9V 14 18C 19F 23F conj vaccine.  On the same day of the vaccinations the patient developed a temperature of 103 degrees Fahrenheit and developed seizures.  Unspecified medical attention was sought and it was reported that the patient was hospitalized for three or more days.  The physician suspected the measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live as cause.  No information was reported regarding the present status of the patient.  No product quality complaint was involved.  The physician considered the seizures and temperature of 103 degrees Fahrenheit to be disabling.  Additional information has been requested.
Seizures Hx of prior seizure disorder. Not on medication.  Narrative:  Employee had seizure after receiving vaccine. Hx of seizure disorder, not on medication. Treated in ER with Ativan. Seizure resolved.
Body has began to have all over rash. Blisters. Losing skin losing hair. Burning and itching. White blood cell count off
Varicella given on 9/30/03, pt presented on 10/20/03 with 3 day h/o rash. Rash was fluid filled vesicles on waist, R axilla.
On 1/9 the site started extreme itching. The next day I realized the site was very red, about 3?x2?. It is still itching, I?m using hydrocortisone cream, the redness is going away but still tea around the perimeter.
Shortly after 1st dose (within 1 week), I developed shortness of breath. At first, it was intermittent, then as time progressed it became more "permenant". I received the 2nd dose on february 23rd while still experiencing daily shortness of breath. Occasionally experienced loss of taste but that went away. I went to my doctor & he took chest X-Ray. Showed partial "collapse" (right lung not functioning properly) of right lung. My doctor suggested "deep breathing excersizes" to re-expand portion of lung affected by side effect. I need to have additional X-Ray in 2 weeks (March 19th, 2021).
2 hours after receiving the vaccine the patient started with a rash on the extremities which has spread to the trunk despite use of BENADRYL. He had no cough, wheezing, respiratory symptoms. The rash appears consistent with erythema multiforme.
Anxiety; Not able to sleep well; A spontaneous report was received from a consumer concerning a 69-year- old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced anxiety and was not able to sleep.    The patient's medical history was not provided. Concomitant product use was not provided by the reporter.     The patient received their first of two planned doses of mRNA-1273 (Batch number: 026L20A) on 27 Jan 2021.  On 24 Feb 2021, prior to the onset of the symptoms, the patient received their second of two planned doses of mRNA-1273 (Batch number: 002A21A) through unknown route in the left arm for prophylaxis of COVID-19 infection.  On 11 Mar 2021, Patient reported that she was anxious and not able to sleep well. She had taken Xanax and has been having chamomile tea.   Treatment for the event included Xanax.    The patient received both scheduled doses of mRNA-1273 prior to the events; therefore, action taken with the drug in response to the events is not applicable.  The outcome of the events was not reported.
Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. It was reported that there had been no power outages that would have impacted the Moderna vaccine. However, the reporter reiterates that because facility was unable to download the digital data logger, they would need to treat this issue as a temperature excursion. The data logger was unable to download for the months of Dec 2021, Jan 2022, and Feb 2022. They were filling out a temperature excursion assessment at that time. It was reported that no adverse reactions were reported by any patients. No treatment medication was reported.
Nausea, mild headache, muscle soreness, soreness at injection site, very tired.
On day 8 following vaccination I developed severe soreness in lymph nodes/armpit of right arm and a large, 3-inch diameter red rash and swelling at the site of the vaccine injection. I have now had these symptoms for 48 hours.